BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

13859

526953

VENUSREM

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

VENUS REMEDIES LIMITED performance

Today’s low

Today’s high

₹ 300.20 ₹ 316.40
₹ 302.85

52 week low

52 week high

₹ 270.25 ₹ 427.90
₹ 302.85

Open Price

₹ 315.00

Prev. Close

₹ 311.55

Volume (Shares)

22329.00

Total traded value

₹ 67.62

Upper Circuit

₹ 373.85

Lower Circuit

₹ 249.25

info

VENUS REMEDIES LIMITED Share Price Update

As of the latest trading session, VENUS REMEDIES LIMITED share price is currently at ₹ 302.85, which is down by ₹ -8.69 from its previous closing. Today, the stock has fluctuated between ₹ 300.20 and ₹ 316.40. Over the past year, VENUS REMEDIES LIMITED has achieved a return of -7.56 %. In the last month alone, the return has been -4.23 %. Read More...

VENUS REMEDIES LIMITED fundamentals


  • Market cap (Cr)

    404.81

  • P/E Ratio (TTM)

    8.10

  • Beta

    0.84

  • Book Value / share

    392.44

  • Return on equity

    6.18%

  • EPS (TTM)

    32.08

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    24.08

info icon alternate text
  • Market cap (Cr)

    409.29

  • P/E Ratio (TTM)

    8.10

  • Beta

    0.69

  • Book Value / share

    392.44

  • Return on equity

    6.18%

  • EPS (TTM)

    32.08

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    24.08

info icon alternate text

VENUS REMEDIES LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 172.54
Operating Expense 154.83
Net Profit 24.08
Net Profit Margin (%) 13.95
Earnings Per Share (EPS) 18.02
EBITDA 34.56
Effective Tax Rate (%) 17.98
Particulars SEP 2024 (Values in Cr)
Revenue 167.02
Operating Expense 162.92
Net Profit 9.26
Net Profit Margin (%) 5.54
Earnings Per Share (EPS) 6.92
EBITDA 20.98
Effective Tax Rate (%) 37.47
Particulars JUN 2024 (Values in Cr)
Revenue 105.86
Operating Expense 97.34
Net Profit 4.45
Net Profit Margin (%) 4.20
Earnings Per Share (EPS) 3.33
EBITDA 15.84
Effective Tax Rate (%) 55.85
Particulars MAR 2024 (Values in Cr)
Revenue 175.16
Operating Expense 159.61
Net Profit 12.51
Net Profit Margin (%) 7.14
Earnings Per Share (EPS) 9.36
EBITDA 25.18
Effective Tax Rate (%) 35.71
Particulars DEC 2023 (Values in Cr)
Revenue 131.23
Operating Expense 124.53
Net Profit 8.19
Net Profit Margin (%) 6.24
Earnings Per Share (EPS) 6.13
EBITDA 15.41
Effective Tax Rate (%) 10.19
Particulars MAR 2024 (Values in Cr)
Revenue 575.21
Operating Expense 539.88
Net Profit 30.50
Net Profit Margin (%) 5.30
Earnings Per Share (EPS) 22.82
EBITDA 72.20
Effective Tax Rate (%) 34.61
Particulars MAR 2023 (Values in Cr)
Revenue 537.66
Operating Expense 507.50
Net Profit 28.96
Net Profit Margin (%) 5.38
Earnings Per Share (EPS) 21.67
EBITDA 71.70
Effective Tax Rate (%) 28.19
Particulars MAR 2022 (Values in Cr)
Revenue 576.71
Operating Expense 540.47
Net Profit 48.99
Net Profit Margin (%) 8.49
Earnings Per Share (EPS) 37.12
EBITDA 77.25
Effective Tax Rate (%) -9.67
Particulars MAR 2021 (Values in Cr)
Revenue 514.62
Operating Expense 514.77
Net Profit 54.27
Net Profit Margin (%) 10.54
Earnings Per Share (EPS) 43.97
EBITDA 88.07
Effective Tax Rate (%) -32.17
Particulars MAR 2020 (Values in Cr)
Revenue 320.23
Operating Expense 321.26
Net Profit -8.23
Net Profit Margin (%) -2.57
Earnings Per Share (EPS) -6.67
EBITDA 37.84
Effective Tax Rate (%) -31.30
Particulars MAR 2024 (Values in Cr)
Book Value / Share 364.74
ROE % 6.01
ROCE % 8.52
Total Debt to Total Equity 0.09
EBITDA Margin 11.83
Particulars MAR 2023 (Values in Cr)
Book Value / Share 344.38
ROE % 5.90
ROCE % 7.59
Total Debt to Total Equity 0.09
EBITDA Margin 12.66
Particulars MAR 2022 (Values in Cr)
Book Value / Share 329.50
ROE % 9.69
ROCE % 7.76
Total Debt to Total Equity 0.11
EBITDA Margin 11.73
Particulars MAR 2021 (Values in Cr)
Book Value / Share 313.18
ROE % 10.59
ROCE % 7.55
Total Debt to Total Equity 0.38
EBITDA Margin 13.39
Particulars MAR 2020 (Values in Cr)
Book Value / Share 262.01
ROE % -0.96
ROCE % 2.38
Total Debt to Total Equity 0.79
EBITDA Margin 13.60
Particulars MAR 2024 (Values in Cr)
Book Value / Share 380.48
ROE % 6.18
ROCE % 8.61
Total Debt to Total Equity 0.08
EBITDA Margin 12.55
Particulars MAR 2023 (Values in Cr)
Book Value / Share 357.63
ROE % 6.24
ROCE % 7.89
Total Debt to Total Equity 0.08
EBITDA Margin 13.34
Particulars MAR 2022 (Values in Cr)
Book Value / Share 336.21
ROE % 11.53
ROCE % 9.39
Total Debt to Total Equity 0.10
EBITDA Margin 13.39
Particulars MAR 2021 (Values in Cr)
Book Value / Share 313.10
ROE % 8.42
ROCE % 6.00
Total Debt to Total Equity 0.36
EBITDA Margin 12.56
Particulars MAR 2020 (Values in Cr)
Book Value / Share 269.21
ROE % -0.41
ROCE % 2.61
Total Debt to Total Equity 0.76
EBITDA Margin 14.57
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 68.09
Total Assets 626.82
Total Liabilities 626.82
Total Equity 487.55
Share Outstanding 13366988
Price to Book Ratio 0.86
Return on Assets (%) 4.54
Return on Capital (%) 5.39
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 54.44
Total Assets 601.08
Total Liabilities 601.08
Total Equity 460.33
Share Outstanding 13366988
Price to Book Ratio 0.45
Return on Assets (%) 4.41
Return on Capital (%) 5.29
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 50.39
Total Assets 579.81
Total Liabilities 579.81
Total Equity 440.44
Share Outstanding 13366988
Price to Book Ratio 0.80
Return on Assets (%) 7.02
Return on Capital (%) 8.43
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 31.41
Total Assets 555.85
Total Liabilities 555.85
Total Equity 400.28
Share Outstanding 12341988
Price to Book Ratio 0.88
Return on Assets (%) 11.11
Return on Capital (%) 13.68
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 2.12
Total Assets 643.77
Total Liabilities 643.77
Total Equity 323.37
Share Outstanding 12341988
Price to Book Ratio 0.08
Return on Assets (%) -1.55
Return on Capital (%) -2.08
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 67.64
Total Assets 641.26
Total Liabilities 641.26
Total Equity 508.59
Share Outstanding 13366988
Price to Book Ratio 0.86
Return on Assets (%) 4.75
Return on Capital (%) 5.57
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 53.30
Total Assets 608.89
Total Liabilities 608.89
Total Equity 478.04
Share Outstanding 13366988
Price to Book Ratio 0.45
Return on Assets (%) 4.75
Return on Capital (%) 5.61
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 49.96
Total Assets 578.66
Total Liabilities 578.66
Total Equity 449.41
Share Outstanding 13366988
Price to Book Ratio 0.80
Return on Assets (%) 8.46
Return on Capital (%) 10.04
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 30.24
Total Assets 546.81
Total Liabilities 546.81
Total Equity 400.18
Share Outstanding 12341988
Price to Book Ratio 0.88
Return on Assets (%) 9.92
Return on Capital (%) 12.12
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1.44
Total Assets 644.26
Total Liabilities 644.26
Total Equity 332.25
Share Outstanding 12341988
Price to Book Ratio 0.08
Return on Assets (%) -1.27
Return on Capital (%) -1.69
Particulars MAR 2024 (Values in Cr)
Net Income 44.64
Cash from Operations 52.76
Cash from Investing -7.20
Cash from Financing -1.08
Net change in Cash 28.99
Free Cash Flow 62.08
Particulars MAR 2023 (Values in Cr)
Net Income 37.93
Cash from Operations 36.62
Cash from Investing -50.82
Cash from Financing -0.56
Net change in Cash -14.76
Free Cash Flow 44.44
Particulars MAR 2022 (Values in Cr)
Net Income 36.40
Cash from Operations 41.10
Cash from Investing -16.72
Cash from Financing -9.47
Net change in Cash 14.89
Free Cash Flow 41.10
Particulars MAR 2021 (Values in Cr)
Net Income 25.11
Cash from Operations 108.39
Cash from Investing 56.49
Cash from Financing -162.24
Net change in Cash 26.08
Free Cash Flow 108.39
Particulars MAR 2020 (Values in Cr)
Net Income 0.77
Cash from Operations 63.16
Cash from Investing -4.74
Cash from Financing -73.00
Net change in Cash -0.14
Free Cash Flow 70.94
Particulars MAR 2024 (Values in Cr)
Net Income 46.65
Cash from Operations 50.86
Cash from Investing -6.94
Cash from Financing 0.00
Net change in Cash 28.43
Free Cash Flow 59.91
Particulars MAR 2023 (Values in Cr)
Net Income 40.32
Cash from Operations 28.05
Cash from Investing -50.81
Cash from Financing 0.00
Net change in Cash -22.75
Free Cash Flow 35.85
Particulars MAR 2022 (Values in Cr)
Net Income 44.67
Cash from Operations 41.00
Cash from Investing -16.75
Cash from Financing -9.12
Net change in Cash 15.12
Free Cash Flow 54.68
Particulars MAR 2021 (Values in Cr)
Net Income 17.61
Cash from Operations 108.89
Cash from Investing 55.98
Cash from Financing -161.87
Net change in Cash 26.44
Free Cash Flow 108.89
Particulars MAR 2020 (Values in Cr)
Net Income 2.54
Cash from Operations 63.30
Cash from Investing -4.63
Cash from Financing -72.34
Net change in Cash 0.75
Free Cash Flow 70.97
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

VENUS REMEDIES LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
302.85 -2.79 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 313.90
  • 26 Days 313.00
  • 10 Days 317.00
  • 50 Days 310.00
  • 12 Days 316.90
  • 100 Days 311.80
  • 20 Days 314.60
  • 200 Days 316.90
314.37 PIVOT

First Support

308.03

First Resistance

317.88

Second Support

304.52

Second Resistance

324.22

Third Support

298.18

Third Resistance

327.73

RSI

48.95

ADX

22.44

MACD

5.61

Williams % R

-63.57

Commodity Channel Index (CCI)

-3.62

Date

2025-04-30

Week

12784.00

Same Day

11931.00

Month

16797.00

1 Year

0.84

3 Year

0.82

Over 1 Month

-4.23%

down

Over 1 Year

-7.56%

down

Over 3 Months

2.36%

down

Over 3 Years

1.57%

down

Over 6 Months

-2.21%

down

Over 5 Years

42.63%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

VENUS REMEDIES LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
0.0%
Promoter Holdings
0.0%
FII
0.0%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category

News

Left Arrow
Right Arrow

VENUS REMEDIES LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
23 Sep 2013 3.0 Final 25 Sep 2013 Equity shares
20 Sep 2012 3.0 Final 24 Sep 2012 Equity shares
22 Sep 2011 3.0 Final 25 Sep 2011 Equity shares
23 Sep 2010 3.0 Final 25 Sep 2010 Equity shares
17 Sep 2009 3.0 Final 20 Sep 2009 Equity shares
12 Sep 2008 4.0 Final 16 Sep 2008 Equity shares
18 Sep 2007 3.0 Final 20 Sep 2007 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
23 Sep 2013 3.0 Final 25 Sep 2013 Equity shares
20 Sep 2012 3.0 Final 24 Sep 2012 Equity shares
22 Sep 2011 3.0 Final 25 Sep 2011 Equity shares
23 Sep 2010 3.0 Final 25 Sep 2010 Equity shares
17 Sep 2009 3.0 Final 20 Sep 2009 Equity shares
12 Sep 2008 4.0 Final 16 Sep 2008 Equity shares
18 Sep 2007 3.0 Final 20 Sep 2007 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

VENUS REMEDIES LIMITED Share Price

Incorporated in 1989 Venus Remedies Ltd (formerly known Venus Glucose Pvt Ltd), was converted into Public Limited Company in 1994 and then changed into Venus Remedies Limited. The Company was promoted and managed by Chaudhary & Family. The Company is one of the handful player in pharmaceutical sector to launch injectables globally. It has manufacturing facilities in Panchkula and Baddi , and research and development centre under the name of Venus Medicine Research Centre (in India). In priority, the Company was mainly engaged in I/V Fluids & Injectables, Ceftazidime, Amlodipine, Gliclazide, Lisinopril, etc.

The production was started in 1991 with Intravenous/Intramuscular injectible forms at Panchkula district at Haryana. In 1994 it introduced Eye/Ear/Nose drops. The company received the certificate as 'WHO-GMP' as specified by WHO,Geneva. Venus Remedies set up a Cephalosporin project with an Australian collaboration with US-FDA standards at a cost of Rs.4.5 crores. The company is manufacturing injections for the top companies like Panacea Biotech ltd,Morepan Labortories ltd etc.

In 2001 with the help of Product Development Committee(PDC) Venus Remedies had introduced 13 new products in the Animal Health Division namely Megox-3000,Paroxin-3000,Pisa-3000,Mical,Ronid,Dexolyte and Detox.

The year 2005-06 saw many new milestone achievements by the Company like commercial operation of its most modern and techno-savvy manufacturing unit at Baddi, formation of a WOS in Germany and acquisition of a running, German-GMP certified pharmaceutical unit at Werne, Germany, launch of its second R&D Product after DCGI Approval etc. There was a rigorous activity for development on all fronts and the Company made huge investments in projects at Panchkula, Baddi and now at Werne, Germany for renovations, new Projects and acquisition as well.

The Company was the first to launch Injection Meropenem in Paediatric Dosage of 125 mg in its Domestic Marketing during the year 2006-07. It further launched fourth research product, a fixed dose combination of cephalosporin with aminoglycoside under the 'Tobracef' brand in 2008-09. It launched its anti-cancer drug 'Docetaxel' in Europe by end 2011, launched ACHNIL, the once-a-day pain management therapy in India in 2011; launched 'Cytomib', a first-time therapy against blood cancer in 2011; launched 'Taxedol' in three
strengths-20 mg, 80 mg and 120 mg in 2012.

In 2013, the Company established pre-clinical proof of concept for its Drug -Protein-Polymer- Conjugate (DPPC); introduced Ready-to-Use a Single Vial Taxedol in India; launched 'Trois', a miracle nano-emulsion for arthritic Pain; launched 'Elores' - CSE 1034, a US patent protected product in India, launched its first OTC product 'Ezenus'.

In 2014, the Company launched ELORES, an antibiotic to fight superbugs'. In 2021-22, it launched first product in the consumer healthcare space, R3SET - a Pain Management solution. Besides this, Venpocare dealing with Wound Healing was also launched during year 2022. To make internal processes smart and streamlined, many solutions including an automated order processing system, retail billing system, new warehouse (VFC) with barcode automation, etc. were launched. For quicker and more effective decision-making, a
BI tool like Tableau was also launched in 2022.

Parent organization Indian Private
NSE symbol VENUSREM
Founded 1989
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Venus Remedies Ltd?

Answer Field

The share price of Venus Remedies Ltd for NSE is ₹ 302.85 and for BSE is ₹ 306.2.

What is the Market Cap of Venus Remedies Ltd?

Answer Field

The market cap of Venus Remedies Ltd for NSE is ₹ 4,04.81 Cr. and for BSE is ₹ 4,09.29 Cr. as of now.

What is the 52 Week High and Low of Venus Remedies Ltd?

Answer Field

The 52 Week High and Low of Venus Remedies Ltd for NSE is ₹ 427.90 and ₹ 270.25 and for BSE is ₹ 427.30 and ₹ 272.20.

How to Buy Venus Remedies Ltd share?

Answer Field

You can trade in Venus Remedies Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Venus Remedies Ltd?

Answer Field

The 1 year returns on the stock has been -7.56%.

What is the Current Share Price of Venus Remedies Ltd?

Answer Field

Venus Remedies Ltd share price is for NSE ₹ 302.85 & for BSE ₹ 306.2 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Venus Remedies Ltd Share?

Answer Field

The market cap of Venus Remedies Ltd for NSE ₹ 4,04.81 & for BSE ₹ 4,09.29 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Venus Remedies Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Venus Remedies Ltd share is 8.10.

What is the PB ratio of Venus Remedies Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Venus Remedies Ltd share is 392.44.

How to Buy Venus Remedies Ltd Share?

Answer Field

You can trade in Venus Remedies Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Venus Remedies Ltd Share on Bajaj Broking App?

Answer Field

To buy Venus Remedies Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Venus Remedies Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|